Investments
422Portfolio Exits
84Funds
3Partners & Customers
1About F-Prime Capital
F-Prime Capital, formerly Fidelity Biosciences and Devonshire Investors, is a global venture capital firm investing in life sciences, healthcare and technology. Since 1969, F-Prime has worked closely with entrepreneurs and academics to create innovative solutions to some of the world's most significant challenges in healthcare and technology.
F-Prime Capital Headquarter Location
1 Main Street 13th Floor
Cambridge, Massachusetts, 02142,
United States
617-231-2400
Expert Collections containing F-Prime Capital
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find F-Prime Capital in 2 Expert Collections, including Synthetic Biology.
Synthetic Biology
382 items
CB Insights Healthcare Smart Money Investors - 2020
25 items
Track the world's top-performing VC investors in healthcare. Firms are presented in alphabetical order.
Research containing F-Prime Capital
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned F-Prime Capital in 6 CB Insights research briefs, most recently on Feb 16, 2021.


Aug 4, 2020
Here Are Q2’s Most Active Healthcare InvestorsLatest F-Prime Capital News
May 12, 2022
Mathison’s holistic DEI platform has seen 800%+ growth over the past two years May 12, 2022 11:00 AM Eastern Daylight Time NEW YORK--( BUSINESS WIRE )-- Mathison , the only solution to provide employers with an end-to-end Diversity, Equity and Inclusion (DEI) hiring and retention platform, has announced today the close of its $25 million Series A led by F-Prime Capital, with participation from Bain Capital Ventures, SemperVirens, ANIMO Ventures, GTM Fund, Gaingels and JP Morgan. The new injection of funding will be used to continue to build out our data and analytics capabilities, scale our go-to-market team and increase our collective impact with employers. As part of the round, John Lin of F-Prime Capital joins the board. This is a moment when leaders want to make real progress on diversity, but miss the insights and capabilities needed to take action. According to a study conducted by Deloitte , 69% of executives say diversity is their most important priority right now, 93% of employers lack a robust diversity hiring solution, 76% of them haven’t set diversity goals and nearly half of those who have goals are not yet confident they will achieve them. “Existing solutions are disjointed and their high price tags have made DEI cost prohibitive and operationally cumbersome to manage,” said Arthur Woods, Co-Founder of Mathison. “After leading years of research across hundreds of employers, we recognized employers were missing the proper insights and systems to support their DEI efforts at scale. We designed Mathison so employers could build a holistic DEI strategy that they could immediately mobilize into action and continuously manage across their organization.” Mathison has pioneered the first DEI Operating System to give employers a single place to manage their: DEI measurement, benchmarking and reporting Diversity sourcing to expand the hiring pipeline DEI training and tools to shift behavior and reduce bias Designed to integrate into employers’ existing systems, Mathison features DEI tools that can be implemented into every employee’s daily workflow and a comprehensive dashboard of DEI metrics for leaders. “Just as every essential business function, from payroll to sales, has had a system of record, the same should exist for DEI,” said John Lin, investor from F-Prime Capital. “Mathison is the first and only end-to-end platform for DEI, bringing together analytics and strategy into an intelligent platform that encourages employers to activate training and hiring with insights.” Mathison has made a measurable collective impact, sourcing over 50,000 underrepresented candidates for employers, supporting the development of hundreds of new equitable talent policies across over 30 industries, and engaging more than 10,000 employees in DEI training to date. “We assessed countless DEI tools and Mathison was the only real solution that enabled us to measure, source and engage the team all at once,” said Kathy Schrepferman, a talent leader from Cornerstone OnDemand. “We feel grateful to have founded Mathison with the intentional mission of making DEI a possibility for organizations through transparency, measurement and accountability. Our community and movements have galvanized around our efforts to strive for more,” said Dave Walsh, CEO and Co-Founder of Mathison. “Our system is designed to instill real meaningful change and we are excited to use this funding to propel the DEI efforts of thousands of organizations to create a more equitable future”. Mathison uses its own product for DEI and includes 50% women, 72% working parents and 50% people of color on its management team. To learn more about Mathison, please visit www.mathison.io About Mathison Mathison is the world’s first DEI Operating System. Its end-to-end platform transforms organizations’ hiring and retention strategies to increase diversity with a single place to build their DEI action plan, measure growth and mobilize every team with education and tools. A leader in DEI innovation and research, their book, Hiring for Diversity, was named a bestseller and is referenced by organizations across the globe. Mathison works with a wide range of employers of all sizes including companies like Sonos, TripAdvisor, 23andMe, HelloFresh, Bowery Farms, Bristol Myers Squibb and non-profits from Sundance Film to The World Economic Forum. For more information, please visit: www.mathison.io . About F-Prime Capital: F-Prime Capital is a global venture capital firm investing in healthcare and technology. For the past 50 years, our independent venture capital group has had the privilege of backing great entrepreneurs building groundbreaking companies. With over two billion dollars under management and a global portfolio of more than 160 companies, we champion those dedicated to creating positive change in the world. In healthcare, we focus on therapeutics, medtech, and health IT & services in a stage-agnostic fashion. In technology, we focus on enterprise software, fintech and frontier tech; while we're early-stage investors by choice, we'll back exceptional teams at any stage. Our team of investors, engineers, doctors, and scientists is committed to bringing the insight, domain expertise, and relationships required to help our companies make a transformational impact. F-Prime is headquartered in Cambridge, MA, with offices in London, UK and San Francisco, CA. For more information, please visit fprimecapital.com and follow us on Twitter and LinkedIn. Contacts
F-Prime Capital Investments
422 Investments
F-Prime Capital has made 422 investments. Their latest investment was in Mathison as part of their Series A on May 5, 2022.
F-Prime Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
5/12/2022 | Series A | Mathison | $25M | Yes | 3 | |
4/11/2022 | Series B | Invetx | $60.5M | Yes | 2 | |
4/5/2022 | Series A | Eleos Health | $20M | Yes | 4 | |
3/30/2022 | Series A | |||||
3/28/2022 | Series A |
Date | 5/12/2022 | 4/11/2022 | 4/5/2022 | 3/30/2022 | 3/28/2022 |
---|---|---|---|---|---|
Round | Series A | Series B | Series A | Series A | Series A |
Company | Mathison | Invetx | Eleos Health | ||
Amount | $25M | $60.5M | $20M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 3 | 2 | 4 |
F-Prime Capital Portfolio Exits
84 Portfolio Exits
F-Prime Capital has 84 portfolio exits. Their latest portfolio exit was Ivenix on March 31, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
3/31/2022 | Acquired | 6 | |||
1/11/2022 | Acq - Talent | 2 | |||
1/6/2022 | Acquired | 2 | |||
Date | 3/31/2022 | 1/11/2022 | 1/6/2022 | ||
---|---|---|---|---|---|
Exit | Acquired | Acq - Talent | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 6 | 2 | 2 |
F-Prime Capital Acquisitions
1 Acquisition
F-Prime Capital acquired 1 company. Their latest acquisition was Citrine Medicine on January 01, 2019.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
1/1/2019 | Series A | $80M | Acq - Fin | 1 |
Date | 1/1/2019 |
---|---|
Investment Stage | Series A |
Companies | |
Valuation | |
Total Funding | $80M |
Note | Acq - Fin |
Sources | 1 |
F-Prime Capital Fund History
3 Fund Histories
F-Prime Capital has 3 funds, including Fidelity Biosciences.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
Fidelity Biosciences | Early-Stage Venture Capital | Closed | 1 | ||
Fidelity Biosciences Fund II | |||||
Beacon Bioventures Fund III LP |
Closing Date | |||
---|---|---|---|
Fund | Fidelity Biosciences | Fidelity Biosciences Fund II | Beacon Bioventures Fund III LP |
Fund Type | Early-Stage Venture Capital | ||
Status | Closed | ||
Amount | |||
Sources | 1 |
F-Prime Capital Partners & Customers
1 Partners and customers
F-Prime Capital has 1 strategic partners and customers. F-Prime Capital recently partnered with Atlas on October 10, 2014.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
10/21/2014 | Partner | United States | Meet Unum, a new immunotherapy biotech with Fidelity, Atlas and Sanofi in its corner As the promise of harnessing the immune system to fight cancer grabs headlines around the industry , venture stalwarts Fidelity Biosciences and Atlas Venture have teamed up to launch Unum Therapeutics , a Cambridge , MA , startup with a hybrid approach to the field . | 1 |
Date | 10/21/2014 |
---|---|
Type | Partner |
Business Partner | |
Country | United States |
News Snippet | Meet Unum, a new immunotherapy biotech with Fidelity, Atlas and Sanofi in its corner As the promise of harnessing the immune system to fight cancer grabs headlines around the industry , venture stalwarts Fidelity Biosciences and Atlas Venture have teamed up to launch Unum Therapeutics , a Cambridge , MA , startup with a hybrid approach to the field . |
Sources | 1 |
F-Prime Capital Team
7 Team Members
F-Prime Capital has 7 team members, including current President, Chief Operating Officer, Thomas Beck.
Name | Work History | Title | Status |
---|---|---|---|
Thomas Beck | President, Chief Operating Officer | Current | |
Stephen Knight | President, Managing Partner | Current | |
Mary Bevelock Pendergast | Globespan Capital Partners, and Pretzel Logic Software | Chief Financial Officer | Current |
Shervin Ghaemmaghami | Senior Vice President | Current | |
David Jegen | Managing Partner | Current |
Name | Thomas Beck | Stephen Knight | Mary Bevelock Pendergast | Shervin Ghaemmaghami | David Jegen |
---|---|---|---|---|---|
Work History | Globespan Capital Partners, and Pretzel Logic Software | ||||
Title | President, Chief Operating Officer | President, Managing Partner | Chief Financial Officer | Senior Vice President | Managing Partner |
Status | Current | Current | Current | Current | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.